82W.DU is trading 3% down at €29.16 as rival LifeMD's new telehealth program for Xyosted testosterone injections pressures the company's competitive position.
- The move extends a multi-day pullback for the stock following a sharp rally over the past week.
- The launch of the competing telehealth program has triggered a decline in Hims & Hers’ shares as investors weigh the impact on its market standing.